Skip to main content

Oral Abstracts

Oral Abstract Presentations: Session 1A
March 24, 2020
10:15-11:30 AM

Heat Treatment Exposes a Partially Cleaved 27 Amino Acid Peptide (P27) on the Fusion (F) Protein of Infectious Respiratory Syncytial Virus (RSV)
Wanderson Rezende
Graduate Student, Baylor College of Medicine, Houston, TX

Development of a Novel Respiratory Syncytial Virus Controlled Human Infection Model: Phase 1 Study of rRSV A/Maryland/001/11 in Healthy Adult Volunteers
Kawsar R. Talaat, MD
Assistant Professor, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD

Synthetic DNA Vaccines Adjuvanted with pIL-33 Drive Liver Localized T Cells and Provide Protection from Plasmodium Challenge in a Mouse Model
Sophia Reeder
PhD Candidate, University of Pennsylvania, Philadelphia, PA

Recombinant Full-Length Circumsporozoite Protein-Based Vaccine for Plasmodium falciparum is Highly Immunogenic at Low Doses in Phase 1 Testing Among Healthy Baltimore Volunteers
DeAnna J. Friedman-Klabanoff, MD
Postdoctoral Fellow, University of Maryland School of Medicine, Baltimore, MD

A Novel Methodological Framework Revealed New Antigenic Sites and a Complex Antigenic Diversification of GII.4 Noroviruses
Gabriel I. Parra, PhD
Principal Investigator, Division of Viral Products, US Food and Drug Administration, Silver Spring, MD


Oral Abstract Presentations: Session 1B
March 24, 2020
10:15-11:30 AM

Safety of Measles-Containing Vaccines in School-Age Children Previously Diagnosed with Autism Spectrum Disorders
Ousseny Zerbo, PhD
Research Scientist, Kaiser Permanente Vaccine Study Center, Oakland, CA

Age Inappropriate Influenza Vaccination in Infants Less Than 6 Months Old, Reports to the US Vaccine Adverse Event Reporting System (VAERS), 2010–2018
Tiffany A. Suragh, MPH
Associate Service Fellow Health Scientist, Centers for Disease Control and Prevention, Atlanta, GA

Observational Study of Routine Use of 9-Valent Human Papillomavirus Vaccine: Safe in More Than 140,000 Individuals
John R. Hansen, MPH
Group Leader Consulting, Kaiser Permanente Vaccine Study Center, Oakland, CA

Safety and Immunogenicity of Coadministration of Meningococcal Type A Vaccine with Typhoid Conjugate Vaccine in Healthy Children 15–23 Months of Age in Burkina Faso
Matthew B. Laurens, MD, MPH
Associate Professor, Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD

Vaccine Hesitancy and Infant Vaccination under India’s Universal Immunization Program
Abram L. Wagner, PhD, MPH
Research Assistant Professor, University of Michigan, Ann Arbor, MI


Oral Abstract Presentations: Session 2A
March 24, 2020
2:30-3:30 PM

Multi-Modal Vaccination Targeting Clostridioides difficile Based on a Chromosomally Integrated, Attenuated Salmonella Typhimurium Vector Protects Mice from Challenge
Kaitlin Winter
PhD Candidate, McGill University, Montreal, Quebec, Canada

Effectiveness of Cell Culture-Based Inactivated Influenza Vaccine against Medically-Attended, Laboratory-Confirmed Influenza in Northcentral Wisconsin, 2018–2019
Kayla E. Hanson, MPH
Epidemiologist, Marshfield Clinic Research Institute, Marshfield, WI

In Vivo Assembly of Nanoparticles Achieved Through Synergy of Structure-Based Protein Engineering and Synthetic DNA Generates Enhanced Adaptive Immunity
Ziyang Xu
MD/PhD Candidate, Graduate Research Student, Wistar Institute, Philadelphia, PA

Therapeutic Application of a YS1646 Salmonella Typhimurium Vectored Vaccine in Mice Chronically-Infected with Schistosoma mansoni
Adam S. Hassan
PhD Student, McGill University, Montreal, Quebec, Canada


Oral Abstract Presentations: Session 2B
March 24, 2020
2:30-3:30 PM

Immunoinformatic Analyses of HLA-Presented Zika Virus Peptides Identified using Tandem Mass Spectrometry
Stephen N. Crooke, PhD
Research Fellow, Mayo Clinic, Rochester, MN

First-in-Human Phase 1 Trial of the Safety and Immunogenicity of a Trivalent Salmonella Conjugate Vaccine That is Intended to Prevent Invasive Non-Typhoidal Salmonella Disease and Typhoid Fever in sub-Saharan Africa
Wilbur H. Chen, MD, MS
Associate Professor of Medicine, Center for Vaccine Development and Global Health, Baltimore, MD

From Field to a Vaccine Candidate: A Proof-of-Concept Study for Advancing Influenza Pandemic Preparedness
Terianne M. Wong, PhD
Biologist, Centers for Disease Control and Prevention, Atlanta, GA

Genome-Wide Association Study Identified Important Determinants of Antibody Response to Mumps Vaccine
Inna G. Ovsyannikova, PhD
Professor of Medicine, Mayo Clinic, Rochester, MN


Oral Abstract Presentations: Session 3A (Non-CME)
March 24, 2020
3:45-4:30 PM

Using Systems Serology to Predict the Development of Broadly Neutralizing Antibodies Following Influenza Vaccination
Todd J. Suscovich, PhD
Chief Technical Officer, SeromYx Systems Inc., Cambridge, MA

Immune-Engineered Antigen Designed to Harness CD4+ T Cell Memory Improves Protection Against Lethal Avian H7N9 Influenza
Lauren Meyers, PhD
Postdoctoral Research Fellow, EpiVax Inc., Providence, RI

Development of Single Dose Vaccines for Emerging and Re-Emerging Infectious Diseases; Preclinical Data for Ebola, Marburg, Lassa Fever, and Zika as Examples
Farshad Guirakhoo, PhD
Chief Scientific Officer, GeoVax, Inc., Smyrna, GA


Oral Abstract Presentations: Session 3B (Non-CME)
March 24, 2020
3:45-4:30 PM

Phase 3 Double-Blind, Randomized, Controlled Trials, PROTECT and CONSTANT, Investigating Seroprotection Rates of the Trivalent Hepatitis B Vaccine, Sci-B-Vac® Compared to Engerix® in Adults
Joanne Langley, MD, MS
Professor, Canadian Immunization Research Network, Departments Of Pediatrics And Community Health And Epidemiology, Canadian Center For Vaccinology, Halifax, Nova Scotia, Canada

HBV-24: Immunogenicity and Safety of HEPLISAV-B® in Hemodialysis Patients
Randall N. Hyer, MD, PhD, MPH
Vice President, Clinical Development and Medical Affairs, Dynavax Technologies Corporation, Emeryville, CA

Vaccine Effectiveness Against Influenza-Related Hospitalizations and Serious Respiratory Events During the 2017–2018 Influenza Season: Comparison between Quadrivalent Cell-Based and Egg-Based Influenza Vaccines
Girishanthy Krishnarajah
Seqirus, Summit, NJ